InsiderSignal.AI

InsiderSignal.ai

WGS - Genedx Holdings Corp.

Insider Sale by Stueland Katherine (CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

2 days ago, Stueland Katherine, serving as CEO at Genedx Holdings Corp. (WGS), sold 2,172 shares at $65.19 per share, for a total transaction value of $141,595.00. Following this transaction, Stueland Katherine now holds 93,216 shares of WGS.

This sale represents a 2.00% decrease in Stueland Katherine's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Wednesday, April 29, 2026 and publicly disclosed via SEC Form 4 filing on Friday, May 1, 2026, 2 days after the trade was made.

Genedx Holdings Corp. operates in the HEALTHCARE sector, specifically within the DIAGNOSTICS & RESEARCH industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Stueland Katherine

Stueland Katherine

CEO

Katherine Stueland is the President and Chief Executive Officer of GeneDx Holdings Corp. (Nasdaq: WGS), a global leader in genomics focused on genetic testing for rare diseases, hereditary cancers, and other conditions.[[1]](https://www.opko.com/investors/news-events/press-releases/detail/438/opko-health-appoints-katherine-stueland-as-president-and-ceo-of-genedx)[[2]](https://www.genedx.com/leadership-team/katherine-stueland/)[[5]](https://www.genedx.com/leadership) Appointed to the role in June 2021 by OPKO Health, she previously served as Chief Commercial Officer at Invitae Corporation, where she helped transform the company from private to public with a market cap over $6 billion, and held positions at Dendreon Corporation and TAP Pharmaceuticals, contributing to the launch of the first cancer immunotherapy and other key therapeutics.[[1]](https://www.opko.com/investors/news-events/press-releases/detail/438/opko-health-appoints-katherine-stueland-as-president-and-ceo-of-genedx)[[2]](https://www.genedx.com/leadership-team/katherine-stueland/) With over two decades in healthcare, Stueland has driven GeneDx's turnaround by emphasizing exome and genome testing, nearly tripling sequencing capacity to over 750,000 exomes and genomes, achieving profitability, and growing the market cap to nearly $3 billion as of recent reports, with 2024 revenue of $302 million.[[2]](https://www.genedx.com/leadership-team/katherine-stueland/)[[3]](https://fortune.com/2025/03/31/genedx-ceo-genetic-testing-women-in-tech/)[[4]](https://www.insideprecisionmedicine.com/topics/molecular-dx/katherine-stueland-the-diagnostic-odyssey-era-ends-with-early-genomics/) Her patient-centric approach stems from early advocacy for genetic disease research; she holds a bachelor’s degree in science and English literature from Miami University in Oxford, Ohio, and serves on the JED Foundation Leadership Council.[[2]](https://www.genedx.com/leadership-team/katherine-stueland/) As a 10% owner and corporate insider, she recently sold shares in October 2025 for tax obligations.[[7]](https://fr.tradingview.com/news/tradingview:71dc8fde72a80:0-genedx-holdings-corp-executives-sell-shares-for-tax-obligations/)

View full insider profile →

Trade Price

$65.19

Quantity

2,172

Total Value

$141,595.00

Shares Owned

93,216

Trade Date

Wednesday, April 29, 2026

2 days ago

SEC Filing Date

Friday, May 1, 2026

Filed 2 days after trade

HEALTHCAREDIAGNOSTICS & RESEARCH

Discussion

Sign in to join the discussion.
Loading comments…
View news mentioning WGS

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/6108554

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime